49. The device for use according to any one of claims 43 to 48, wherein said patient is free from respiratory depression for at least 1 hour following said treatment.

50. The device for use according to claim 49, wherein said patient is free from respiratory depression for at least 2 hours following said treatment.

51. The device for use according to claim 50, wherein said patient is free from respiratory depression for at least 4 hours following said treatment.

52. The device for use according to claim 51, wherein said patient is free from respiratory depression for at least 6 hours following said treatment.

53. The device for use according to any one of claims 43 to 52, wherein said patient is in a lying, supine, or recovery position.

54. A use of the pharmaceutical formulation according to any one of claims 1 to 13 to prepare a medicament for treatment of opioid overdose or a symptom thereof in a patient.

55. The use of the pharmaceutical formulation according to claim 54 wherein said patient is an opioid overdose patient or a suspected opioid overdose patient.

56. The use of the pharmaceutical formulation according to claim 54 or 55 wherein the patient exhibits one or more symptoms of respiratory depression, central nervous system depression, cardiovascular depression, altered level consciousness, miotic pupils, hypoxemia, acute lung injury, aspiration pneumonia, sedation, hypotension, unresponsiveness to stimulus, unconsciousness, stopped breathing; erratic or stopped pulse, choking or gurgling sounds, blue or purple fingernails or lips, slack or limp muscle tone, contracted pupils, or vomiting.

57. The use of the pharmaceutical formulation according to any one of claims 54 to 56 wherein the patient exhibits respiratory depression.

58. The use of the pharmaceutical formulation according to claim 57, wherein said respiratory depression is caused by an illicit use of opioids, or by an accidental misuse of opioids during medical opioid therapy.

59. The use of the pharmaceutical formulation according to any one of claims 54 to 58, wherein said patient is free from respiratory depression for at least 1 hour following said treatment.

60. The use of the pharmaceutical formulation according to claim 59, wherein said patient is free from respiratory depression for at least 2 hours following said treatment.

61. The use of pharmaceutical formulation according to claim 60, wherein said patient is free from respiratory depression for at least 4 hours following said treatment.

62. The use of a pharmaceutical formulation according to claim 61, wherein said patient is free from respiratory depression for at least 6 hours following said treatment.

63. The use of the pharmaceutical formulation according to any one of claims 54 to 62, wherein said patient is in a lying, supine, or recovery position.

64. The use of the pharmaceutical formulation according to any one of claims 54 to 63, wherein the medicament is a nasal spray.

65. The pharmaceutical formulation of any one of claims 1 to 13 for treating an eating disorder in a patient wherein said eating disorder is binge eating, bulimia, or stimulus-induced over-eating.

66. The device of any one of claims 14 to 31 for treating an eating disorder in a patient wherein said eating disorder is binge eating, bulimia, or stimulus-induced over-eating.